Literature DB >> 2426189

Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth.

J Gordon, L Walker, G Guy, G Brown, M Rowe, A Rickinson.   

Abstract

Highly purified resting (Go) B lymphocytes were monitored for their response to transforming Epstein-Barr virus (B95-8 strain), to a non-transforming mutant (P3HR-1) containing a deletion in the EBNA-2 coding region, and to inactivated virus of either type. All preparations induced an early appearance of two activation antigens, which included the CD23,p45 ("Blast-2') antigen. Thus, virus binding was sufficient for an initial activation step. Further change required an active viral genome. Infection with the P3HR-1 strain prompted the exit of cells out of Go but led to an arrest in the early G1 phase of the cycle. While initially showing sequels to activation indistinguishable from those observed with P3HR-1 virus, cells infected with B95-8 virus continued through G1 to express late activation antigens, enter S-phase and complete the replicative cycle. The addition of the phorbol ester TPA was found to compensate for the abortive cell cycle entry achieved with the P3HR-1 mutant, but could not supplement the minimal activation observed with inactivated virus. These findings demonstrate that the Epstein-Barr virus undermines three separate control points in the growth cycle of human B lymphocytes, and exploits three distinct viral signals to achieve this end.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426189      PMCID: PMC1453114     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Control of human B-lymphocyte replication. I. Characterization of novel activation states that precede the entry of G0 B cells into cycle.

Authors:  L Walker; G Guy; G Brown; M Rowe; A E Milner; J Gordon
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

2.  Modulation of cell surface iron transferrin receptors by cellular density and state of activation.

Authors:  J W Larrick; P Cresswell
Journal:  J Supramol Struct       Date:  1979

3.  Characterization of a human B cell-specific antigen (B2) distinct from B1.

Authors:  L M Nadler; P Stashenko; R Hardy; A van Agthoven; C Terhorst; S F Schlossman
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

4.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

Review 5.  Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma.

Authors:  K Nilsson; G Klein
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

6.  Increased expression of I-region-associated antigen (Ia) on B cells after cross-linking of surface immunoglobulin.

Authors:  J J Mond; E Seghal; J Kung; F D Finkelman
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

7.  Immortalized B lymphocytes produce B-cell growth factor.

Authors:  J Gordon; S C Ley; M D Melamed; L S English; N C Hughes-Jones
Journal:  Nature       Date:  1984 Jul 12-18       Impact factor: 49.962

8.  Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity.

Authors:  M Rowe; J E Hildreth; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1982-04-15       Impact factor: 7.396

9.  Transferrin receptors in human tissues: their distribution and possible clinical relevance.

Authors:  K C Gatter; G Brown; I S Trowbridge; R E Woolston; D Y Mason
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

10.  Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus.

Authors:  J Gordon; S C Ley; M D Melamed; P Aman; N C Hughes-Jones
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  29 in total

1.  Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.

Authors:  R J Murray; L S Young; A Calender; C D Gregory; M Rowe; G M Lenoir; A B Rickinson
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

Review 2.  Molecular basis for Epstein-Barr virus induced pathogenesis and disease.

Authors:  C Sample; E Kieff
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes.

Authors:  C M Rooney; M Brimmell; M Buschle; G Allan; P J Farrell; J L Kolman
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus.

Authors:  A J Sinclair; P J Farrell
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.

Authors:  S Schlager; S H Speck; M Woisetschläger
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.

Authors:  R Fåhraeus; A Jansson; A Ricksten; A Sjöblom; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

7.  Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP.

Authors:  R Moorthy; D A Thorley-Lawson
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.

Authors:  S D Abbot; M Rowe; K Cadwallader; A Ricksten; J Gordon; F Wang; L Rymo; A B Rickinson
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

9.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

10.  Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin.

Authors:  D Liebowitz; E Kieff
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.